Patrys (ASX:PAB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Patrys (ASX:PAB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Patrys Secures 50% Revenue Share in IP Commercialisation
Patrys Secures 50% Revenue Share in Deoxymab IP Commercialisation Deal with Yale University
Becoming a substantial holder
Change of Director's Interest Notices x4
Notification regarding unquoted securities - PAB
Cleansing Notice
Application for quotation of securities - PAB
Proposed issue of securities - PAB
Results of Meeting
Patrys advances RLS-2202 toward Phase 1 Clinical Trial
Patrys appoints CMAX and Alithia for Phase 1A clinical trial of RLS-2202, targeting Q3 2026 start
Appendix 4C - Quarterly - 31 March 2026 - Updated
Letter to Shareholders - General Meeting
Notice of General Meeting/Proxy Form
Appendix 4C - Quarterly - 31 March 2026
Cleansing Notice
Application for quotation of securities - PAB
Proposed issue of securities - PAB
$3.2 million Placement to Advance Clinical Trials
Patrys raises A$3.2 million to advance injectable quetiapine clinical trials
Trading Halt